1155269-72-9

Upstream product

• 137102-65-9 (R)-(2-amino-1-phenyl-ethyl)-carbamic acid tert-butyl ester 
• 306935-55-7 4,5-dichloro-6-methyl-2-(pyridin-2-yl)pyrimidine 
• 1155269-71-8 C₂₃H₂₆ClN₅O₂ 

Downstream Products

• 1155269-76-3 C₂₀H₂₀ClN₅O₂S 
• 1155269-79-6 C₃₀H₄₀ClN₇O₂ 
• 1155269-87-6 C₃₄H₅₂ClN₇OSi 
• 1155269-73-0 C₃₀H₃₈ClN₇O₃ 
• 1155269-74-1 C₃₃H₄₈ClN₇O₂Si 
• 1155269-77-4 C₂₉H₃₈ClN₇O₄S 
• 1155269-78-5 C₃₂H₄₈ClN₇O₃SSi 
• 1155269-02-5 C₂₇H₃₄ClN₇O₂ 
• 1155269-13-8 C₂₈H₃₆ClN₇O₂ 
• 1155269-00-3 C₂₅H₃₀ClN₇O 
• 1155269-11-6 C₂₆H₃₂ClN₇O 
• 1155269-09-2 C₂₅H₃₂ClN₇ 
• 1155269-10-5 C₂₇H₃₆ClN₇O 
• 1155269-14-9 C₂₆H₃₄ClN₇ 

Relevant academic research and scientific papers

Pyridinylpyrimidines selectively inhibit human methionine aminopeptidase-1

Cellular protein synthesis is initiated with methionine in eukaryotes with few exceptions. Methionine aminopeptidases (MetAPs) which catalyze the process of N-terminal methionine excision are essential for all organisms. In mammals, type 2 MetAP (MetAP2)

INHIBITORS OF HUMAN METHIONINE AMINOPEPTIDASE 1 AND METHODS OF TREATING DISORDERS

Described herein are novel pyrimidine-pyridine compounds, methods of inhibiting methionine aminopeptidase and treating disorders (or symptoms thereof) associated with methionine aminopeptidase, wherein a compound of the invention is administered to a subject.